Phathom Pharmaceuticals Inc PHAT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$5.25 up $0.17, 3.35% at close Nov 6
Last close · Previous close $5.08
- Market cap
- $424.73MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.01Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$5.25up $0.17, 3.35%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$5.08Nov 5
- Volume1.77MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.80MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $5.02 to $18.31; now $5.25
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PHAT trailed the S&P 500 in all 6 periods.
| Period | PHAT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PHAT: down 22.6% S&P 500: down 5.6% | PHAT trailed the S&P 500 by 17.0 percentage points Trailed |
| 3M | PHAT: down 37.4% S&P 500: down 4.1% | PHAT trailed the S&P 500 by 33.3 percentage points Trailed |
| YTD | PHAT: down 68.4% S&P 500: up 8.7% | PHAT trailed the S&P 500 by 77.1 percentage points Trailed |
| 1Y | PHAT: down 59.7% S&P 500: up 10.9% | PHAT trailed the S&P 500 by 70.6 percentage points Trailed |
| Long term | ||
| 3Y | PHAT: down 34.0% S&P 500: up 75.0% −12.9% vs +20.5% a year | PHAT trailed the S&P 500 by 109.0 percentage points Trailed |
| 5Y | PHAT: down 76.5% S&P 500: up 67.8% −25.1% vs +10.9% a year | PHAT trailed the S&P 500 by 144.3 percentage points Trailed |
$10,000 invested in PHAT 5 years ago (Nov 5, 2021) would be worth about $2,350 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
PHAT trailed the S&P 500 in all 6 periods.
| Period | PHAT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PHAT: down 22.6% S&P 500: down 5.6% | PHAT trailed the S&P 500 by 17.0 percentage points Trailed |
| 3M | PHAT: down 37.4% S&P 500: down 4.3% | PHAT trailed the S&P 500 by 33.1 percentage points Trailed |
| YTD | PHAT: down 68.4% S&P 500: up 7.8% | PHAT trailed the S&P 500 by 76.2 percentage points Trailed |
| 1Y | PHAT: down 59.7% S&P 500: up 9.7% | PHAT trailed the S&P 500 by 69.4 percentage points Trailed |
| Long term | ||
| 3Y | PHAT: down 34.0% S&P 500: up 68.8% −12.9% vs +19.1% a year | PHAT trailed the S&P 500 by 102.8 percentage points Trailed |
| 5Y | PHAT: down 76.5% S&P 500: up 56.9% −25.1% vs +9.4% a year | PHAT trailed the S&P 500 by 133.4 percentage points Trailed |
$10,000 invested in PHAT 5 years ago (Nov 5, 2021) would be worth about $2,350 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$54.60
Closing high on . Now 90.4% below that record.
Split-adjusted daily closes since Oct 25, 2019.
Stock splits
PHAT hasn’t split since its price history begins in 2019.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$1.01 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 1.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - −4.95%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $752.24MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own PHAT DCF in Excel. Value Phathom Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $274.88Mup 86.8%
- Net income
- −$83.00M
- Diluted EPS
- −$1.01
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $29.66M | −$74.45M | −$1.00 |
| Q1 FY25 (Mar 31, 2025) | $28.52M | −$94.32M | −$1.31 |
| Q2 FY25 (Jun 30, 2025) | $39.50M | −$75.81M | −$1.05 |
| Q3 FY25 (Sep 30, 2025) | $49.50M | −$29.97M | −$0.41 |
| Q4 FY25 (Dec 31, 2025) | $57.58M | −$21.15M | −$0.27 |
| Q1 FY26 (Mar 31, 2026) | $58.30M | −$30.37M | −$0.37 |
| Q2 FY26 (Jun 30, 2026) | $74.27M | −$17.58M | −$0.21 |
| Q3 FY26 (Sep 30, 2026) | $84.72M | −$13.90M | −$0.16 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$143.88M | −$3.89 |
| FY22 (Dec 31, 2022) | $0.00 | −$197.72M | −$5.05 |
| FY23 (Dec 31, 2023) | $682.00K | −$201.59M | −$3.93 |
| FY24 (Dec 31, 2024) | $55.25M | −$334.33M | −$5.29 |
| FY25 (Dec 31, 2025) | $175.11M | −$221.25M | −$3.03 |
Margins
- Gross 80.7%
- Operating −9.3%
- Net −30.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$21.04MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$20.74MLast 12 months
- Capital spending$302.00KLast 12 months
- −7.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $127.75MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $187.42MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$514.93MAs of Sep 30, 2026
- Net debt$327.51MAs of Sep 30, 2026
- 1.76As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −26.9%Last 12 months
Over the last 12 months, Phathom Pharmaceuticals’s net loss was 26.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA ® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PHAT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PHAT stock FAQ
What is PHAT stock’s price today?
Phathom Pharmaceuticals (PHAT) traded at $5.25 at the close on , up $0.17 (3.35%) from the previous close of $5.08. Over the past 52 weeks it has traded between $5.02 and $18.31.
If you invested $1,000 in PHAT 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PHAT on would be worth about $235 at the close on , a total return of −76.5%. The same $1,000 would be worth $403 if invested one year ago. Past performance doesn’t predict future returns.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market capitalization is about $424.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $5.25 (how market cap works). Phathom Pharmaceuticals reported 80.90M shares outstanding at the end of its latest quarter ().
What is PHAT’s P/E ratio?
PHAT’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.01).
How much revenue does Phathom Pharmaceuticals make?
Phathom Pharmaceuticals reported $274.9 million of revenue over the four quarters to , up 86.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $84.7 million, up 71.1% from a year earlier.
Is Phathom Pharmaceuticals profitable?
Not over the four quarters to . Phathom Pharmaceuticals reported a net loss of $83.0 million across those four quarters on $274.9 million of revenue.
What are PHAT’s earnings per share?
PHAT’s diluted earnings per share were −$1.01 over the four quarters to , compared with −$3.77 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.16 per share, against −$0.41 a year earlier (how EPS works).
Does PHAT pay a dividend?
Phathom Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is PHAT’s 52-week high and low?
Over the past 52 weeks PHAT has traded as low as $5.02 and as high as $18.31. At $5.25 at the close on , it is 71.3% below that high and 4.7% above the low.
What is PHAT’s all-time high?
PHAT’s highest closing price was $54.60 on , adjusted for stock splits. At $5.25 at the close on , it is 90.4% below that record.
Has PHAT stock ever split?
No. PHAT hasn’t split since its price history begins in 2019.
How has PHAT stock performed?
Including dividends and measured to the close on , PHAT has returned −68.4% so far this year and −59.7% over the past year, and −76.5% over five years (−25.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Phathom Pharmaceuticals in?
Phathom Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in New Jersey, USA.
What exchange does PHAT trade on?
Phathom Pharmaceuticals trades on the Nasdaq under the ticker symbol PHAT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.